H-1B sponsorship profile: Immunova Therapeutics. Across U.S. Department of Labor LCA disclosures, Immunova Therapeutics filed 2 Labor Condition Applications covering 2 H-1B worker positions between fiscal year 2023 and fiscal year 2023. The employer’s DOL certification rate sits at 50% (1 certified of 2 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Immunova Therapeutics’s H-1B petitions range from $110,947 at the low end to $111,000 at the high end, with a petition-weighted average of $110,974. That range reflects the mix of occupations the company sponsors, led by Scientist (2 petitions at $110,974 avg). H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Immunova Therapeutics is headquartered in Monrovia, CA under NAICS code 5417, and places H-1B workers across 1 state, most heavily in CA. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Immunova Therapeutics ranks. By H-1B petition volume, Immunova Therapeutics is #48,558 of 119,880 employers nationally and #8,876 of 22,893 employers headquartered in CA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.